News Center

• Jul. 13

  2022

  CSPC's COVID-19 Vaccine Approved for Clinical Trials

  On April 3, 2022, CSPC Pharmaceutical Group Co., Ltd. (Stock code 1093. HK) announced that the COVID-19 mRNA vaccine SYS6006 ("the product") developed by the Group was approved by the National Medical Products Administration for clinical trials in China.

• May. 09

  2022

  AlaMab Therapeutics--INNOVATIVE FIRST-INCLASS ANTIBODY DRUGS

  Over the past couple of years, antibodies have become the bestselling drugs in the pharmaceutical market. Currently, antibody-based therapeutics relish unprecedented success, growth in research, and recognition of their potential.

• Feb. 19

  2022

  His Story with Mitoxantrone Hydrochloride Liposome Injection

  A patient story with mitoxantrone hydrochloride liposome injection

• Sep. 14

  2021

  CSPC Open Day Showcases Innovation Achievements

  “As a Hebei-based pharmaceutical company with a global vision, CSPC is driven by innovation which has accelerated its development and transformation. We are glad to introduce CSPC and Chinese pharmaceutical innovation to more people and show them the magic of innovation at CSPC,” said the person in charge of the event.

• Jan. 20

  2021

  Six Women Volunteers of CSPC in Huo-Yan Air Lab

  Six Women of CSPC volunteered at Huo-Yan Air Lab to help prevent and control the pandemic resurgence in Shijiazhuang.

• May. 16

  2020

  ANVISA Declares Two CSPC Products Exempt from Inspection

  Two products of the CSPC entered the Brazilian market without inspection through mutual recognition procedure.